SynthesisAtencion primaria2002
[Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis].
Synthesis in Atencion primaria, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vaccines for preventing pneumococcal infection in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Efficacy of pneumococcal vaccination in adults: a meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Pooled it
- Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Clinical and vaccine immunology : CVI · 2016Review
- Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.Health economics review · 2012Article
- Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.BMC public health · 2010Article
- [Pneumococcal vaccination in the over-65 population].Atencion primaria · 2007Article
- Advances in pneumococcal vaccines: what are the advantages for the elderly?Drugs & aging · 2007Review
- [EVAN-50 study: Effectiveness of polysaccharide pneumococcus vaccine in preventing pneumococcal infections in the over-50 population].Atencion primaria · 2006Article
- [Guidelines for the management of community pneumonia in adult who needs hospitalization].Medicina intensiva · 2005Article
- [EVAN-65 project: evaluation of the effectiveness of pneumococcus vaccination in the elderly population over 65].Atencion primaria · 2004Article
- [Meta-analyses do not show that pneumococcal vaccine is ineffective in preventing pneumococcal pneumonia in patients over 65].Atencion primaria · 2003Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimEstimate pneumococcal vaccine effectiveness in preventing Streptococcus pneumoniae illness in the elderly.
designSystematic review and meta-analysis. DATA SOURCE. MEDLINE, years 1964 to the 2000; EMBASE, from 1988 to the 2000; Cochrane Library, identified studies and previously published systematic reviews citations peruse, and contacts with field experts. STUDY SELECTION: Clinical trials, cohort and case-control studies, published in Spanish, English or French, that estimated pneumococcal disease rates in vaccinated or not vaccinated elderly. DATA EXTRACTION: The studies were valued independently by four investigators with predefined criteria of validity, such as results comparing rates of disease caused by serotypes included in the vaccine, random allocation, double blind design, included subjects pertaining to the same study base, and losses of less than 10% in clinical trials and 20% in observational studies.
resultsEight clinical trials considered the relative risk (RR) of pneumococcal pneumonia, three did not make estimations on pneumonia originated by serotypes included in the vaccine and only one study fulfilled all the inclusion criteria. Vaccinated versus not vaccinated pneumococcal pneumonia RR was 0.86 (95%CI, 0.24 to 2.99). Vaccine effectiveness was 14% (95%CI, -199 to 76%). Ten studies performed estimations on the effectiveness of the vaccine on invasive disease by vaccine serotypes. Of these, two clinical trials and two observational studies fulfilled the required quality criteria. RR of invasive disease was of 0.68 (95%CI, 0.39-1.18); vaccine effectiveness was 32% (95%CI, 18-61%).
conclusionsNo evidence was found supporting pneumococcal vaccine effectiveness to reduce or avoid S. pneumoniae disease in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.